However, a higher E2F1 expression level was correlated with a higher risk of tumor recurrence in male GC patients (Table 4), suggesting that E2F1 can serve as a predictive biomarker for tumor recurrence risk in male GC patients. Here, E2F1 is linked to neoplasm.